The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Advances in the Development of Vaccines against Neisseria meningitidis
Open accessAbstract
A lthough two centuries have passed since Vieusseux described epidemic meningococcal disease, 1 Neisseria meningitidis remains a leading cause of meningitis and sepsis.Overwhelming meningococcal disease can develop rapidly and is associated with mortality rates exceeding 20%. 2 Thus, efforts to control the disease have focused on vaccination.In the past, vaccines against meningococcal disease have failed to provide immunogenicity and long-term protection in infants, who are at greatest risk.Although recent vaccines have improved coverage for this age group, there is still no broadly effective vaccine against N. meningitidis group B (NMB), now the predominant disease-causing isolate in industrialized countries.Developments during the past decade have renewed hopes for solving this seemingly intractable problem.Knowledge of the meningococcal genome has led to the identification of novel antigens that have been incorporated into the NMB vaccines now being studied in clinical trials.However, it remains unclear whether these vaccines will provide sufficient immunogenicity in infants as well as wide-ranging coverage.This review highlights the evolution of meningococcal vaccines in general and discusses strategies being used to overcome the barriers to developing vaccines against NMB. Epidemiology of N. meningitidis InfectionMeningococcal disease is a global health problem.The World Health Organization estimates that there are 1.2 million cases of invasive meningococcal disease and 135,000 related deaths annually.3 Although the disease occurs sporadically in industrialized countries, with an incidence of 0.35 cases per 100,000 population in the United States and of 1.01 per 100,000 in Europe (ranging from 0.25 to 4.4 per 100,000 in Italy and Malta, respectively), 4 the major disease burden is in the nonindustrialized countries.A recent epidemic in Nigeria resulted in 4164 cases and 171 deaths in 1 week alone.5 The meningococcus is pathogenic only in humans.It colonizes the nasopharynx asymptomatically in up to 40% of the adult population but occasionally causes invasive disease.When the infection is classified according to the polysaccharide capsule surrounding the bacterium, only six capsular groups (A, B, C, W-135, X, and Y) are associated with invasive disease.6 The epidemiology of disease caused by these groups varies: group A is responsible for large epidemics in Africa, in which the incidence approaches 1000 cases per 100,000 population (and may involve environmental factors), whereas groups B and C cause disease predominantly in industrialized and newly industrialized countries.2,6 Recently, groups W-135 and X (predominantly in Africa) and group Y (in the United States and other countries) have emerged as important disease-causing isolates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
Trotter, C. L., Andrews, N. J., Kaczmarski, E. B., Miller, E., & Ramsay, M. E. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16725-1 · Cited by 571
Kelly, D. F., Pollard, A. J., & Moxon, E. R. (2005) · JAMA · doi:10.1001/jama.294.23.3019 · Cited by 113
Cited by
Infections of People with Complement Deficiencies and Patients Who Have Undergone Splenectomy
Ram, S., Lewis, L. A., & Rice, P. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00048-09 · Cited by 405
Ng, B., Chu, A., & Khan, M. M. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002468 · Cited by 301
Vogel, U., Taha, M.-K., Vazquez, J. A., Findlow, J., Claus, H., Stefanelli, P., Caugant, D. A., Kriz, P., Abad, R., Bambini, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70006-9 · Cited by 285
Self-citationSialic acid metabolism and sialyltransferases: natural functions and applications
Li, Y., & Chen, X. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4040-1 · Cited by 281
Vesikari, T., Esposito, S., Prymula, R., Ypma, E., Kohl, I., Toneatto, D., Dull, P., & Kimura, A. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61961-8 · Cited by 279
Metadata
- Authors
- Tan, L. K. K., Carlone, G. M., & Borrow, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-04-22
- Volume
- 362
- Issue
- 16
- Pages
- 1511-1520
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1976881351
- Cited by
- 233
- References
- 2
- FWCI
- 26.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in the Development of Vaccines against Neisseria meningitidis. https://app.cochat.ai/papers/10.1056/nejmra0906357
- The paper
- Tan, L. K. K., Carlone, G. M., & Borrow, R. (2010). Advances in the Development of Vaccines against Neisseria meningitidis. New England Journal of Medicine. https://doi.org/10.1056/nejmra0906357
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.